Alaunos Therapeutics Investor Relations Material
Latest events
Q1 2023
Alaunos Therapeutics
Q1 2025
15 May, 2025
Q4 2024
30 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Alaunos Therapeutics Inc
Access all reports
Alaunos Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapies for cancer treatment. The company specializes in T-cell receptor (TCR) therapies, leveraging its proprietary Sleeping Beauty non-viral gene transfer platform to engineer T-cells that target solid tumors with specific genetic mutations. Alaunos’s pipeline targets a range of cancers, including lung, ovarian, and pancreatic cancers. The company is headquartered in Houston, Texas, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
TCRT
Country
🇺🇸 United States